VentriPoint Diagnostics Ltd.

VentriPoint Diagnostics Ltd.

May 12, 2011 11:00 ET

VentriPoint Diagnostics Ltd.: The Riley Hospital for Children at Indiana University Health System is Fifth Installation of VMS™ Heart Analysis System

Research group to compare VMS™ to standard-of-care using MRI in congenital heart disease

SEATTLE, WASHINGTON--(Marketwire - May 12, 2011) - VentriPoint Diagnostics Ltd. ("VentriPoint") (TSX VENTURE:VPT) (PINK SHEETS:VPTDF) as part if its controlled rollout strategy, is announcing a new VMS™ research site for right heart analysis in the United States at Riley Hospital for Children at Indiana University Health System. The clinical group will initially be using the VMS™ to look at patients who have had surgery for congenital heart disease, but still have significant problems with the right ventricle and must be followed long-term.

"We are pleased to be a research site of the VentriPoint Medical System (VMS™)", said Tiffanie R. Johnson, MD, FAAP, FACC; Associate Professor of Clinical Pediatrics and Radiology and Imaging Sciences Section of Pediatric Cardiology, Riley Hospital for Children, Indiana University. "We hope the system will provide a quick and accurate way to assess the effects of the disease on the right ventricle. Cardiac MRI is the best option at this time, so we plan to compare data between the two modalities. I am enthusiastic about the advantages and accuracy of the VMS™ for patients with congenital heart disease."

"Starting this collaborative prospective study with VentriPoint has been an unbelievable learning opportunity for which I am grateful", said Dr. Jennifer K.E. Whitham, who will be part of the team of cardiologists conducting the research. "I am excited to help further the field of pediatric cardiology and enhance the care we provide to our patients here at Riley Hospital for Children with new advances in cardiac non-invasive imaging, such as is offered by the VMS™."

"The reception by the cardiology community of our VMS™ heart analysis device continues to be exceptional", stated Dr. George Adams, CEO of VentriPoint. "Groups continue to express additional unmet needs they wish to address - Riley Hospital for Children will study the extra value provide by the 3D VMS™ shape analysis as compared with their standard-of-care in patients with congenital heart disease."

This is the 5th installation of a VMS™ with 1 in Canada, 1 in Europe and 3 in the United States. Additional installations are in process and will be announced as each system is installed. VentriPoint plans to have ten systems operational in the US, Europe and Canada by the end of the second calendar quarter this year.

About RileyHospital for Children at Indiana University Health System

Riley Hospital for Children at Indiana University Health continues to be recognized as one of the top children's hospitals and has achieved many distinctions, establishing the hospital as one of the premier pediatric research facilities in the United States. The Hospital has more than 245,000 inpatient and outpatient pediatric visits annually from across the state, nation and the world and offers one of the nation's largest outpatient care facilities for children, the world's largest pediatric sleep disorders center and one of the nation's largest three autism treatment centers. Riley at IU Health's relationship with IU Health and its strong affiliation with the IU School of Medicine -- an institution that continues to advance its reputation by engaging in cutting-edge research and innovating new therapies. Website is

About VentriPoint Diagnostics Ltd.

VentriPoint has created a diagnostic ultrasound tool to monitor patients with heart disease, a leading cause of death in developed countries. The VMS™ is the first cost-effective and accurate diagnostic tool for measuring right ventricle heart function. Congenital heart disease is the first application in a suite of applications for all major heart diseases including pulmonary hypertension, cardiovascular disease and heart failure - a multibillion-dollar market potential. Canada and Europe (CE Mark) have granted approval for the sale of VentriPoint's VMS™ diagnostic tool and VentriPoint is pursuing the US-FDA approval through the 510(k) process.

FORWARD-LOOKING STATEMENTS: The statements made in this press release that are not historical facts contain forward-looking information that involves risk and uncertainties. All statements, other than statements of historical facts, which address VentriPoint's expectations, should be considered forward-looking statements. Such statements are based on management's exercise of business judgment as well as assumptions made by and information currently available to management. When used in this document, the words "may", "will", "anticipate", "believe", "estimate", "expect", "intend" and words of similar import, are intended to identify any forward-looking statements. You should not place undue reliance on these forward-looking statements. These statements reflect a current view of future events and are subject to certain risks and uncertainties as contained in the Corporation's filings with Canadian securities regulatory authorities. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results could differ materially from those anticipated in these forward-looking statements. The Corporation undertakes no obligation, and does not intend, to update, revise or otherwise publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of any unanticipated events. Although management believes that expectations are based on reasonable assumptions, no assurance can be given that these expectations will materialize.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information